- Solid Biosciences press release ( NASDAQ: SLDB ): Q3 Net loss for the third quarter of 2022 was $20.4 million
- Solid had $142.2 million in cash, cash equivalents and available-for-sale securities as of September 30, 2022,
-
Research and development expenses for the third quarter of 2022 were $14.0 million, compared to $14.4 million for the third quarter of 2021.
-
General and administrative expenses for the third quarter of 2022 were $7.1 million, compared to $7.1 million for the third quarter of 2021.
For further details see:
Solid Biosciences reports Q3 results